Mesa Laboratories Inc., headquartered in Lakewood, reported financial results for its third fiscal quarter ending December 31, 2025. The company, which specializes in life science tools and quality control solutions, experienced a 3.6% increase in total revenues, reaching $65.1 million compared to the same period last year. Operating income surged 38% to $7.975 million, while net income skyrocketed by 317% to $3.63 million.
Organic revenue growth was also positive, with a 3.6% rise reported, and non-GAAP organic revenues increased 5.7% when excluding diagnostics revenue from its Clinical Genomics division in China. The company reduced its total debt by $8.7 million, bringing its Total Net Leverage Ratio down to 2.62.
CEO Gary Owens emphasized that “steady execution and relatively stable markets across Europe and North America helped deliver 3.6% organic (1.2% core organic) revenues growth in 3Q26 versus the prior year.” He noted strong performance in the Biopharmaceutical Development sector and a recovery in Sterilization and Disinfection Control products. The company remains optimistic about continued growth as market conditions stabilize.
Mesa Laboratories operates across four divisions—Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics—each contributing to the company’s positive quarterly results.
The primary source was GlobeNewswire.
